AQST Aquestive Therapeutics

Aquestive Therapeutics to Announce Third Quarter Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET

Aquestive Therapeutics to Announce Third Quarter Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET
EN
14/10/2020

Underlying

AQSTAquestive Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aquestive Therapeutics

 PRESS RELEASE
Free
AQST Aquestive Thera...

Aquestive Therapeutics Reports Third Quarter 2025 Financial Results an...

Aquestive Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update Planned U.S. launch of Anaphylm™ in the first quarter of 2026, if approved by the FDA Advanced Anaphylm regulatory activities in Canada and the EUAdded clinical leadership to drive long-term successStrengthened balance sheet to support planned commercial launch execution of AnaphylmCompany to host investor call on November 6, 2025, at 8:00am ET WARREN, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company a...

November 5, 2025 1 EN
 PRESS RELEASE
Free
AQST Aquestive Thera...

Aquestive Therapeutics Announces Leadership Expansion to Support Growt...

Aquestive Therapeutics Announces Leadership Expansion to Support Growth Changes strategically aligned to support planned launch of Anaphylm™ (dibutepinephrine) Sublingual Film, if approved by the FDA, and to accelerate the Company’s ongoing development initiatives Matthew Davis, M.D., RPh will join immediately as Chief Development OfficerGary Slatko, M.D., M.B.A, will become interim Chief Medical Officer Peter Boyd, M.B.A, has been promoted to Chief People Officer WARREN, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a...

November 4, 2025 1 EN
 PRESS RELEASE
Free
AQST Aquestive Thera...

Aquestive Therapeutics to Participate in a Fireside Chat Hosted by Pip...

Aquestive Therapeutics to Participate in a Fireside Chat Hosted by Piper Sandler WARREN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that David Amsellem, Sr. Research Analyst at Piper Sandler, will host a live fireside chat with the Company’s management team on November 6, 2025 at 12:00 p.m. ET. The discussion will focus on the Company’s product candidat...

November 3, 2025 1 EN
 PRESS RELEASE
Free
AQST Aquestive Thera...

Aquestive Therapeutics to Attend 2025 ACAAI Annual Meeting

Aquestive Therapeutics to Attend 2025 ACAAI Annual Meeting WARREN, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that multiple presentations highlighting results from the investigational use of its product candidate Anaphylm™ (dibutepinephrine) sublingual film in the treatment of severe allergic reactions, including anaphylaxis, will be featured at the 2025...

October 30, 2025 1 EN
 PRESS RELEASE
Free
AQST Aquestive Thera...

Aquestive Therapeutics to Report Third Quarter 2025 Financial Results ...

Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET WARREN, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the third quarter ended September 30, 2025 and provide an update on recent developments in its business...

October 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch